Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease

Oncologist

Volumn 14, Issue 10, 2009, Pages 963-969

  Damjanov, Nevena ^a   Weiss, Jared ^a   Haller, Daniel G ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colectomy; Colorectal neoplasms; Review literature

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION; COLON RESECTION; COLORECTAL TUMOR; INTESTINE OBSTRUCTION; LIVER TUMOR; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLORECTAL NEOPLASMS; HUMANS; INTESTINAL OBSTRUCTION; LIVER NEOPLASMS; NEOPLASM METASTASIS; PALLIATIVE CARE; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73349105281     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0022     Document Type: Review

References (33)

1. Ries LAG, Melbert D, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2005, based on November 2007 SEER data submission, posted to the SEER website, 2008. Accessed September 29, 2009.
2. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
3. Scoggins CR, Meszoely IM, BlankeCDet al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999;6:651-657.
4. Ruo L, Gougoutas C, Paty PB et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003;196:722-728.
5. Kuo LJ, Leu SY, Liu MC et al. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum 2003;46:1646-1652.
6. Galizia G, Lieto E, Orditura M et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 2008;143:352-358, discussion 358.
7. Rosen SA, Buell JF, YoshidaAet al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000;135:530-534, discussion 534-535.
8. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005;12:637-645.
9. Konyalian VR, Rosing DK, Haukoos JS et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 2007;9:430-437.
10. Tebbutt NC, Norman AR, Cunningham D et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003;52:568-573.
11. Stelzner S, Hellmich G, Koch R et al. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005;89:211-217.
12. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
13. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
14. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
15. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
16. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676.
17. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668-674.
18. Chau I, Allen M, Cunningham D et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer 2003;88:1017-1024.
19. Camúñez F, Echenagusia A, Simo G et al. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 2000;216:492-497.
20. Sarela AI, Guthrie JA, Seymour MT et al. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001;88:1352-1356.
21. Dohmoto M, Hunerbein M, Schlag PM. Palliative endoscopic therapy of rectal carcinoma. Eur J Cancer 1996;32A:25-29.
22. Poultsides G, Servais E, Saltz L et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379-3384.
23. NCI Physician Data Query. Available at: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=463513&version=HealthProfessional& protocolsearchid=5768851. Accessed January 2009.
24. de Gramont A, Figer A, SeymourMet al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
25. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
26. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
27. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
28. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
29. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
30. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
31. Sugrue M, Kozloff M, Hainsworth J et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006;24A:3535.
32. Petrelli NJ. Expressing the prochemotherapy position on treatment of synchronous colorectal metastases in the asymptomatic patient. Ann Surg Oncol 2006;13:137-139.
33. Mentha G, Majno PE, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93:872-878.